Screener / SEC EDGAR /CIK 0001393434 /10-K filed Feb 5, 2026, compared with Mar 3, 2025 /Numbers from the XBRL of the 10-Ks
Nasdaq Health care · Pharmaceuticals

Ocular Therapeutix, Inc OCUL

Compare with peers Embed
Planned sales, announced before they happen

0 trading plans running, 32 Form 144 notices for $3.4M

10-Q, 10-K and Form 144

What OCUL's directors and officers said they would sell, before they sold: trading plans the company reports each quarter, and the Form 144 notices sellers file on the day of a planned sale. Most of these sales are routine, such as selling shares from vesting stock awards.

Plans adopted or ended

Trading plans · XBRL, 10-Q and 10-K

From Feb 21, 2024 to Nov 16, 2026. The thin line is today; a filled bar is a plan still running, a paler one has ended or expired.

InsiderWhatDateReported in
David Robinson
Global Chief Commercial Officer
Adopted 10b5-1 plan Jan 26, 2026 10-Q May 5, 2026
What the company wrote
The following table describes, for the quarterly period covered by this report, each trading arrangement for the sale or purchase of our securities adopted or terminated by our directors and officers that is either (1) a contract, instruction or written plan intended to satisfy the affirmative defense conditions of Rule 10b5-1(c), or a “Rule 10b5-1 trading arrangement”, or (2) a “non-Rule 10b5-1 trading arrangement” (as defined in Item 408(c) of Regulation S-K): ​ ​ ​ ​ ​ ​ ​ Name (Title) Action Taken (Date of Action) Type of Trading Arrangement Nature of Trading Arrangement Duration of Trading Arrangement Aggregate Number of Securities David Robinson (Global Chief Commercial Officer) Adoption (January 26, 2026) Durable Rule 10b5-1 trading arrangement for sell-to-cover transactions relating to all RSUs that have or may be granted Sale Until final settlement of any covered RSUs Indeterminable (1) ​ (1) The number of shares subject to covered RSUs that will be sold to satisfy applicable tax withholding obligations upon vesting is unknown as the number will vary based on the extent to which vesting conditions are satisfied, the market price of the Company’s common stock at the time of settlement and the potential future grant of additional RSUs subject to this arrangement. This trading arrangement, which applies to RSUs that have or may be granted, provides for the automatic sale of shares that would otherwise be issuable on each settlement date of a covered RSU in an amount sufficient to satisfy the applicable withholding obligation, with the proceeds of the sale delivered to the Company in satisfaction of the applicable withholding obligation.
Pravin U. Dugel
Executive Chairman, President and Chief Executive Officer
Adopted 10b5-1 plan Feb 11, 2025 10-Q May 5, 2025
Todd D.C. Anderman
Chief Legal Officer
Adopted 10b5-1 plan Oct 7, 2024 10-Q May 5, 2025
Nadia K. Waheed
Chief Medical Officer
Adopted 10b5-1 plan Jun 1, 2024 10-Q Nov 14, 2024
Donald Notman
Chief Financial Officer
Adopted 10b5-1 plan Mar 15, 2024 10-Q May 7, 2024
Antony Mattessich
President and Chief Executive Officer until April 14, 2024
Adopted 10b5-1 plan Mar 14, 2024 10-Q May 7, 2024
Philip C. Strassburger
General Counsel
Adopted 10b5-1 plan Mar 14, 2024 10-Q May 7, 2024
Pravin U. Dugel
President and Chief Executive Officer, Executive Chairman
Adopted 10b5-1 plan Feb 21, 2024 10-Q May 7, 2024
Sanjay Nayak
Chief Strategy Officer
Adopted 10b5-1 plan Feb 21, 2024 10-Q May 7, 2024
Show the other 1 plans

From the XBRL of the company's 10-Qs and 10-Ks (Regulation S-K Item 408, reported since 2023): 15 filings checked since May 8, 2023.

Notices of planned sales

Form 144 · Form 144 XML, SEC

What the sellers expected to sell on the Form 144 notices filed each month (the value on the notice).

FiledSellerSharesValue
Nov 5, 2026 NAMRATA SAROJ
Officer
35,370 $232K
Oct 8, 2026 TODD ANDERMAN
Officer
11,984 $87K
Oct 2, 2026 PETER KAZUO KAISER
Officer
9,990 $70K
Oct 2, 2026 JEFFREY S. HEIER
Officer
10,869 $77K
Aug 31, 2026 DONALD D NOTMAN JR.
Officer
1,099 $11K
Aug 24, 2026 SANJAY NAYAK
Officer
1,897 $20K
Aug 24, 2026 PRAVIN DUGEL
Officer
21,649 $233K
Aug 24, 2026 JEFFREY S. HEIER
Officer
3,296 $36K
Aug 24, 2026 PETER KAZUO KAISER
Officer
3,035 $33K
Jun 3, 2026 NADIA K. WAHEED
Officer
14,828 $123K
May 26, 2026 SANJAY NAYAK
Officer
1,858 $15K
May 26, 2026 PETER KAZUO KAISER
Officer
2,967 $24K
May 26, 2026 JEFFREY S. HEIER
Officer
3,018 $25K
May 26, 2026 PRAVIN DUGEL
Officer
21,156 $174K
Feb 23, 2026 PETER KAZUO KAISER
Officer
2,810 $23K
Feb 23, 2026 PRAVIN DUGEL
Officer
20,056 $166K
Feb 23, 2026 JEFFREY S. HEIER
Officer
3,057 $25K
Feb 23, 2026 SANJAY NAYAK
Officer
1,759 $15K
Feb 20, 2026 NADIA K. WAHEED
Officer
3,510 $27K
Feb 12, 2026 DONALD D NOTMAN JR.
Officer
11,446 $103K
Feb 12, 2026 PRAVIN DUGEL
Officer
124,882 $1.1M
Feb 12, 2026 STEVE MEYERS
Officer
6,864 $62K
Feb 12, 2026 SANJAY NAYAK
Officer
10,348 $94K
Feb 12, 2026 NADIA K. WAHEED
Officer
7,863 $71K
Feb 4, 2026 STEVE MEYERS
Officer
4,408 $38K
Feb 4, 2026 DONALD D NOTMAN JR.
Officer
6,035 $52K
Feb 2, 2026 DONALD D NOTMAN JR.
Officer
5,455 $50K
Feb 2, 2026 STEVE MEYERS
Officer
3,052 $28K
Nov 24, 2025 PRAVIN DUGEL
Officer
19,530 $235K
Nov 24, 2025 SANJAY NAYAK
Officer
1,878 $23K
Nov 24, 2025 PETER KAZUO KAISER
Officer
3,007 $36K
Nov 24, 2025 JEFFREY S. HEIER
Officer
3,469 $42K
Show the other 24 notices

From the Form 144 XML filed with the SEC, since Nov 24, 2025. The value is the seller's estimate on the notice. "Form 4 sales after" matches the seller's Form 4 sales in the 30 days after the notice, by name; Form 4s go back 180 days.

Sources

Regulation S-K Item 408 in the XBRL of each 10-Q and 10-K (since 2023); the Form 144 XML at the SEC.

Also

Insider trades: the Form 4s for the sales these plans led to.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/OCUL/export.csv") into a cell.

Next:Owners
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.